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Abstract
Background: The use of telehealth to monitor patients from home is on the rise. Telehealth technology is evaluated in a clinical
trial with measures of health outcomes and cost-effectiveness. However, what happens between a technology and the patients is
not investigated during a clinical trial—the telehealth technology remains as a “black box.” Meanwhile, three decades of research
in the discipline of human-computer interaction (HCI) presents design, implementation, and evaluation of technologies with a
primary emphasis on users. HCI research has exposed the importance of user experience (UX) as an essential part of technology
development and evaluation.
Objective: This research investigates the UX of patients with type 2 diabetes mellitus (T2D) with a telehealth in-home monitoring
device to manage T2D from home. We investigate how the UX during a clinical trial can be researched and what a clinical trial
can learn from HCI research.
Methods: We adopted an ethnographic philosophy and conducted a contextual inquiry due to time limitations followed by
semistructured interviews of 9 T2D patients. We defined the method as Clinical User-experience Evaluation (CUE). The patients
were enrolled in a telehealth clinical trial of T2D; however, this research was an independent study conducted by information
technologists and health researchers for a user-centered evaluation of telehealth.
Results: Key analytical findings were that patients valued the benefits of in-home monitoring, but the current device did not
possess all functionalities that patients wanted. The results include patients’ experiences and emotions while using the device,
patients’ perceived benefits of the device, and how patients domesticated the device. Further analysis showed the influence of
the device on patients’ awareness, family involvement, and design implications for telehealth for T2D.
Conclusions: HCI could complement telehealth clinical trials and uncover knowledge about T2D patients’ UX and future design
implications. Through HCI we can look into the “black box” phenomenon of clinical trials and create patient-centered telehealth
solutions.
(JMIR Hum Factors 2019;6(2):e9481)  doi: 10.2196/humanfactors.9481
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Introduction
Background
Type 2 diabetes mellitus (T2D) is currently one of the world’s
fastest-growing diseases; the prevalence of T2D rose from 171
million persons affected in 2000 to 415 million in 2015
worldwide [1]. The total annual global health expenditure for
diabetes in 2015 was US $673 billion. The cost accounted for
12% of the world’s total health expenditure [1].
Treatments for T2D involve diet control, exercise, home blood
glucose testing, and, in some cases, oral medication with or
without insulin [2]. Effective individualized treatments may
also incorporate psychosocial, lifestyle, and other medical
interventions [3].
Technology-mediated treatments, such as telehealth, eHealth,
mHealth to monitor patients from their homes, are on the
increase with chronic diseases such as T2D. Telehealth is the
use of information and communication technology (ICT) to
provide clinical treatments over distances [4]. A common
telehealth treatment for T2D is for patients to send regular blood
glucose data to nurses or health care providers via phone, tablet,
computer, Web-based system, videoconference, phone call, or
short message service (SMS) text [5,6]. A nurse or health care
provider is involved in T2D telehealth treatments continuously,
while the technology intervention remains as a means of
transferring data (eg, blood glucose, blood pressure) and
facilitates the communication between patients and nurses for
better management of T2D [5,6].
During evaluation through randomized clinical trials, telehealth
technology is represented as a “black box.” Systematic reviews
have shown that clinical trials assess “what went in” (eg,
baseline measures) and “what came out” (eg, postintervention
measures). “What happens inside the interventions” (eg, how
patients felt about using the device and the development of the
interventions not achieving a match between technology and
context) is rarely a focus of attention in clinical trials [7,8]. For
example, in a clinical trial of T2D, the long-term blood glucose
HbA1c of patients at baseline is compared against HbA1c at
the end of the trial. Improvements in HbA1c, along with
additional health parameters, are data that the clinical researchers
use to conclude whether a telehealth technology for T2D was
effective or not.
Clinical trials do not investigate the relationship between the
technology and effects of the use on patients as technology
users, how patients interact with these technologies, or how
patients feel when using these technologies [5,8]. However, the
discipline of human-computer interaction (HCI) tends to be
highly divergent in the choice of methods and approaches to
understand humans and their interactions. A common practice
in HCI is to understand user experience (UX) to design and
develop a human-centered technology. UX refers to how a
product behaves and is used by people in the real world [9].
We were interested in solving the “black box” phenomenon of
a telehealth T2D clinical trial. We looked at six common
methods (Table 1) of HCI to explore if we could use one or
more of them during clinical trials to understand the UX of
patients with T2D with telehealth.
Upon investigation of the six methods in Table 1, we concluded
that there was no possibility to conduct a codesign, participatory
design, lead user approach, or empathic design because these
methods are conducted to create new solutions along with
stakeholders. In a clinical trial, a device already in use is selected
already by doctors, nurses, and stakeholders. Next, the
effectiveness of the device is evaluated, and user-centered design
methods are not practiced in a clinical trial. Therefore, we were
only left with two options: applied ethnography and contextual
design inspired by ethnography.
We adopted an ethnographic philosophy for this study to
understand how the situation is in a clinical trial by moving the
researchers into the users’ environment. Due to time and
resource restrictions, we deduced to conduct a contextual inquiry
and observations, followed by a semistructured interview, and
finally another follow-up via survey. This HCI-inspired research
method was named Clinical User-experience Evaluation (CUE)
[6]. We wanted to conduct an independent study from an HCI
perspective; therefore, we went through a process of defining
CUE and its differences from the clinical trial. This paper
presents the results of the UX of patients with T2D with
telehealth.
Table 1. The 6 dominant human-computer interaction methods.
Research orientationKey featureMethod
Researcher moves into users’ worldLong-term immersive fieldwork; observation combined with participationApplied ethnography [10]
Researcher moves into users’ worldAn ethnographic approach to finding the specific needs of users in a work
situation; provides 8 methodological steps
Contextual design [11]
Researcher moves into users’ worldDraws on information about the user and her everyday life, and includes
inspiration for design and empathy, or “a feel” for the user
Empathic design [12]
Users brought into the researcher’s worldUsers who will be using a system are given a role in the design, evaluation,
and implementation of the system
Participatory design [13]
Users brought into the researcher’s worldMay invite users and other people who do not yet know each other; design
a product for a mass market or nonwork contexts
Co-design [14]
Users brought into the researcher’s worldBrings innovative users together, as many ideas of new products or services
originate in the minds and hands of them and not from professional re-
searchers and designers
Lead user approach [15]
JMIR Hum Factors 2019 | vol. 6 | iss. 2 | e9481 | p. 2http://humanfactors.jmir.org/2019/2/e9481/
(page number not for citation purposes)
Jalil et alJMIR HUMAN FACTORS
XSL•FO
RenderX
Research Objective
The research objective was to investigate how to discover
patients’ UX in telehealth, eHealth, and mHealth in a clinical
trial. To pursue the research objective, we answered the
following three questions with the CUE:
1. What happens at the patient’s home during the use of the
telehealth device?
2. How do patients feel while using the telehealth device?
3. Which function(s) and designs of the device satisfies/
dissatisfies the patients?
Methods
Research Method
An investigation through meta-synthesis conducted in 2014 of
past clinical trials of telehealth T2D concluded that there is a
need for new practices that could capture the experience of users
(patients) in a clinical trial [6]. Therefore, we created the CUE.
The CUE consisted of three stages (Figure 1). Stage one was a
contextual inquiry performed in situ at a patient’s home. During
this stage, a patient used the device with the think-aloud method
as one researcher as the observer took notes. This contextual
inquiry was conducted during a patient’s regularly scheduled
time for using the device, in the patient’s home. Stage two was
a semistructured qualitative inquiry into the patients’ experience
and expectations, the questions that developed during stage one,
and anything extra the patient wanted to talk about. The
interview took place directly after stage one on the same day,
while perceptions were still fresh in the mind of the user. Stage
three was an anonymous survey to follow-up with patients the
findings from the first two stages and if there were any changes
in the use of the device. This was conducted 8 months after
stage two. The researchers were ICT researchers from James
Cook University Townsville (Queensland, Australia) who had
no involvement with the clinical trial. Every participant was
enrolled at least 3 months (12 weeks) into the clinical trial to
avoid novelty effects.
During the application of the CUE, health professionals asked
us (the HCI researchers) to articulate the contribution of CUE
as opposed to a clinical trial, especially because the clinical trial
is a 300-year-old methodology [16] used in medical science.
The CUE protocol is compared to the clinical trial in Table 2
to show the differences. Because clinical trials are regulated
protocols, this table supported us to convey the information to
the team of health scientists (nurses and physicians).
Figure 1. The Clinical User-experience Evaluation (CUE) methodology.
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Table 2. Differences between the Clinical User-experience Evaluation (CUE) and clinical trials.
Clinical trialCUEaReview criteria
Investigates patients’ medical condition with an intervention that
can be a drug or a technology
Investigates patients’ experience, understanding, feeling, and
usage of a technology for health care
Investigation
aims
To provide enough evidence for medical practitioners to make
sound judgments
To provide patient feedback about using the trial technologies
and a guide for future improvement of the technology, including
features that were lacking or nonexistent that would benefit the
treatment process
Outcome
Requires large sample population to provide substantial and robust
evidence
A smaller sample population similar to HCIb qualitative user
evaluation is appropriate
Sample size
Rigorous form of testing that must follow HTAc guidelines;
clinical trials often include psychosocial analysis questionnaire
Tests interaction with a device without interfering in any medical
protocols, there is no physical or psychological stress; conducted
at the regular times a patient uses the technology as part of the
overarching clinical trial
Regulations
Carried out by medical staff or caregivers who have either medical
credentials or training in health care and/or social work
Can be carried out by anyone working in the field of HCI with
simple practice and observational skills
Investigator
Larger samples of volunteers are sought who have specific med-
ical conditions
Participants come from the clinical trialRecruitment
Strong, regulated ethical process and abiding by HTA regulationsPrivacy of information is required, and the participant must pro-
vide written consent
Ethics
aCUE: Clinical User-experience Evaluation.
bHCI: human-computer interaction.
cHTA: Health Technology Assessment.
Participants: Inclusion Criteria
The CUE was applied on a clinical trial that was conducted by
Townsville-Mackay Medicare Locals in North Queensland,
Australia [17]. A total of 210 patients were recruited in
Townsville, Mackay, and Brisbane. Participants were referred
by two nurses. The participants of the CUE were (1) enrolled
in the clinical trial, (2) belonged in the intervention group (using
the telehealth device), (3) diagnosed with T2D for at least 12
months, and (4) volunteered to participate in CUE.
Participant Details
Participation in the CUE was voluntary. A total of 12 patients
initially agreed to participate. However, three of them opted out
of the CUE study because they were not available during the
designated time frame. Nine patients participated in the CUE
study. Five of them were considered part of the aging population
with an age of at least 64 years, and four participants were within
the age range of 50 to 63 years (Table 3). Participants were
given pseudonyms that were incredibly different from the
participants’ original names. In addition to the nine participants,
five family members occasionally provided feedback. Of these
five, only two family members permitted us to use their quotes.
Table 3. Participant details (N=9).
Time since diagnosed with
T2D (years)
Time in clinical trial (months)Computer use (hours/week)Age (years)SexParticipants pseudonyms
>125074FemaleUma
>1087070MaleZach
762068FemaleYanicka
>1062066MaleVince
205464MaleBill
255260FemaleHeidi
231255FemaleSerena
16253MalePete
266052MaleTed
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Figure 2. The in-home monitoring device of the clinical trial: a tablet PC, sphygmomanometer, and glucometer.
Equipment
Participants used a tablet computer with an 11-inch screen, an
automatic glucometer, and an automatic sphygmomanometer
(Figure 2). The device had a touchscreen interface and was a
single-user system. A regular patient session entailed a patient
turning on the tablet and waiting to log in automatically. The
patient then looked at the scheduled blood glucose and blood
pressure test that was arranged by the nurse. The patient pricked
a finger to get a drop of blood and put it on a strip for a blood
glucose reading. The strip was then placed in the glucometer.
To get the blood pressure measurement, the patient put an arm
in the sphygmomanometer, which automatically took the
reading.
Data Analysis
Interviews and contextual inquiry sessions were audio recorded.
The recordings were transcribed, and the notes and data from
the contextual inquiry were analyzed using the contextual design
methodology (Multimedia Appendix 1). The semistructured
interviews were analyzed with thematic content analysis; NVivo
10 software was used to manage the analysis process.
Results
The results showed two themes: (1) the current design and how
that fits with the patients’ needs, and (2) the patients’ experience
of using the device depicted through their feelings and
perceptions.
Current Design: Technology-User Fit
Placement of the Device
We found that patients placed the device in different parts of
their homes (Table 4). The patients chose to place the device
in four locations: living room (n=4), bedroom (n=2), study room
(n=2), and patio (n=1). Reasons mentioned were internet or
phone socket availability (n=3), convenience (n=4), comfort
(n=1), and self-motivation (n=1) regarding their choice of device
placement.
Data from the contextual inquiry was first analyzed through
four steps of the contextual design method (see Multimedia
Appendix 1). The results from one exemplary case, Zach’s
sequence model, showed that he had three breaks noted with a
red mark (Figure 3). The breaks were (1) to save data because
previous readings were not saved for the patients, only for the
nurses, (2) to clean his fingertips after the blood test to continue
with the touchscreen, and (3) to use the internet on a different
device because the telehealth device did not have names of all
medications.
Table 4. Placement of the device in the patients’ homes (N=9).
Total for reason, nLocation, nReason
PatioBedroomStudy roomLiving room
3—
—
a12Internet socket
1———1Comfort
41111Convenience
1—1——Self-motivation
1224Total in each room
aRoom-reason not selected.
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Figure 3. Example of one sequence diagram that shows breaks of patient.
Lack of Wireless Capability
The device only functioned with wired internet that had to be
connected through a cable through the telephone port in a
patient’s house. Heidi, Serena, and Uma mentioned that having
wires was a problem of the device:
Apart from when you gotta be home two hours after
eating to do it can be a little bit difficult like, “Oh my
God I have gotta get home,” so, I mean, time-wise
that’s it if I am not gonna be at home. [Heidi]
When Uma traveled, she used a separate glucometer and would
keep her blood glucose readings in a diary. She would later
come home and update her nurses about the data. However, the
device did not allow users to record data manually:
I can take this [her own glucometer that she bought]
with me, I can’t do the blood pressure, I take this with
me and do the blood sugar and then put it down in a
book. [Uma]
Undesirable Experience From Sphygmomanometer
Every patient criticized the sphygmomanometer. It was difficult
to use. It also gave uncomfortable experiences:
The blood pressure cuff I have more difficulty with.
I put it here where my doctor would put it. It repumps,
and it takes ages to do it. It marks my arm. [Yanicka]
Yanicka complained of physical pain around her arm from the
device. She stated that this pain was more than other
sphygmomanometers that she had used in doctor visits.
Lack of Visual Data
In the current system, each time the patients conducted a test,
they were presented with instant data on their blood pressure
and blood glucose levels. However, when the patients conducted
the next scheduled test, they could not see the previous data.
For example, if a patient did a test in the morning and one in
the evening, they were unable to compare the readings, because
the earlier test was not available. Patients expressed their desire
and the importance to see the previous data to help them know
if they were doing better or worse in terms of their blood
glucose:
I know it does it here [glucometer], but it would be
good to see every day’s. But it doesn´t show you. Like
last week I might have been 5.5 and this week I am
7.5. Why? Why am I? Then I would do exactly the
same things that I did last week. [Bill]
Vince and his wife also mentioned the adjustment of insulin,
similar to Heidi. They said that while Vince took insulin and
was adjusting the dosage of the insulin, they would prefer to
see a day-by-day comparison of Vince’s blood sugar in a graph:
It would be much better if he could just push a button
and see the last three weeks of his readings.
Coz he is adjusting his insulin and he needs to
know—all the time. [Vince’s wife]
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Probably I would like to see a graph of my results,
more often. Like even once a month would be good
to show it on a graph. How my results are going,
because you just see number every day, but you want
to know your ups and downs, and you want to know
using that computer why my diabetes goes higher, I
know the reason now why it goes higher, before I
didn´t know the reasons. But now I do. And it’s just
the difference the food that I have eaten, and the foods
prepared, and I have found that because I am
monitoring my blood glucose carefully. [Pete]
Zach stated that graphs are a great tool to compare trends. Zach
was very particular about using a progressive graph. He also
commented that much research is required on how to show the
blood pressure and the blood glucose level in the graph:
There is nothing like graphs to see trends. They have
to display in a sensible way, if that makes sense. I will
be thinking that a progressive graph will do it. [Zach]
Lack of Medication Name
Yanicka stated that the medication that she was taking was not
included in the information sheet listed on the device. This
meant that the database did not contain a full list of all possible
diabetes medications that the patients in this clinical trial were
using. This necessitated Yanicka using another computer to
locate information about the medication that was prescribed for
her:
To see my change of insulin and I couldn’t find on
here, so I went back through here with my computer
and internet. My medicine is also here...and insulin
is not there, but I looked that up at the computer. Not
everyone has that. When I want to see what that thing
do I check it up here. I don’t ever touch the unit
because it automatically shuts down. It’s simple as
that, quite easy to use. Bit challenging at the
beginning. [Yanicka]
Zach reported the same problem—his medication was missing
from the available information sheet on the device.
Mismatch With Life Due to Immobility of the Device
The device currently works only with internet cables. All the
patients stated that a mobile unit would have been much more
suitable than the current device. Uma stated that she could not
carry the device. So she carried a different glucometer to keep
the data for her records:
I can take this with me; I can’t do the blood pressure,
I take this with me and do the blood sugar and then
put it down in a book. [Uma]
Glucometer Discomfort and Pain
When a patient uses a glucometer, a small drop of blood is
obtained by pricking the skin with a lancet. The drop of blood
is placed on a disposable test strip that the meter reads and uses
to calculate the blood glucose level. Slight discomfort is
experienced when the lancet pricks the skin of the finger.
However, T2D patients use a glucometer frequently, often more
than once a day. Some of the patients in this clinical trial
mentioned the discomfort and pain from the glucometer. Ted
stated that after frequent use over a long period, his finger feels
bruised:
Problem I see with this is you have to prick your
finger every time you use it. It’s not that bad but after
a while you are bruising your fingertips sore, so in
that respect I guess it’s not really something that one
looks forwards to going and doing. [Ted]
Every other patient also felt the pain and complained of being
hurt. As a remedy, Zach was interested to see what the scientists
come up with in the future. Ted also mentioned that he wants
science to advance in such a way that a chip can be inserted and
left in a human body so that it will transmit continuous readings
to the machine. In this way, Ted thinks, bruising and pain may
be avoided.
Feelings and Perceptions
Patients used words such as “motivation,” “accountability,”
“safety net,” “habit,” and “awareness” while they expressed
their frustrations with the telehealth device.
Motivation
Two participants, Vince and Heidi, mentioned that using the
device motivated them to manage their diabetes:
And it’s good that they [nurses], that someone else
is keeping an eye on you, back at office, nurses.
[Vince]
And it gives you just that extra push, you know?
[Heidi]
Build a Habit
Pete lives alone, and he stated that he had developed a habit
from using the device for 6 months in the clinical trial. His habit
was measuring his blood glucose and blood pressure early in
the morning before he would engage in his daily life:
I think it’s a great benefit for me, I wish it probably
could stay, and I would like to keep it. I don´t know
how I am gonna go; I am obviously in the habit of
doing it every morning now, I am gonna have it. It´s
a habit now. So next week it’s gonna go, and I can
still maintain the regimen that I am doing it now, you
know. [Pete]
Awareness
Enrollment in the clinical trial had made Serena aware of her
well-being. The device would make her do things regularly.
Serena called this being in a regimen where she had to regularly
monitor and be aware of her blood glucose and her food.
Serena’s son, who was one of the family members to permit his
data to be used in this research, mentioned:
It’s more like a—there’s a regimen for every day 10
minutes before eating and after eating, she tastes it
and morning, afternoon—it’s 10 minutes or 5
minutes—doesn’t affect much. But it improved her
overall awareness. [Serena’s son]
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Vince stated that after he had looked at the results, he felt more
aware and accountable, which made him want to use the device
more:
It [the device] makes you, wanna do it [the blood
glucose reading]. [Vince]
Heidi compared the use of the telehealth device with quitting
smoking. In quit-smoking programs, people are typically
encouraged to call a back-end, or a buddy, each time they have
the urge to smoke. Heidi found using the device a similar
experience as it makes her do the one extra step that she needs
to take:
You know when you haven’t done this for a week, and
oh you should do it. It’s like quitting smoking; you
know that you have to ring up somebody every time
you have to ring up. So, it’s that extra incentive you
know. [Heidi]
Feel Safe
Daily monitoring provided safety and comfort to the patients.
In the case of Vince, daily monitoring made his wife feel safe
that someone was watching over him:
It’s sort of like a safety net. You know there’s someone
in the background always watching and they will ring
you up. [Vince’s wife]
For Uma (a 74-year-old woman living alone), the device was
not of interest. In Uma’s opinion, the use of the device provided
the nurses with the data that they needed and that made her feel
safe. Serena’s son stated that Serena’s enrollment in the trial
and use of the device helped him to look after her.
Reduced Doctor Visits
Patients stated that they had fewer visits to the doctor during
the time enrolled in the clinical trial. They indicated that they
did not have to see a doctor every 3 months, which is the
traditional treatment. Instead, they spoke with the nurse every
2 weeks, which decreased the doctor visits unless there was
something urgent.
Frustrations
Patients had frustrations using the device due to slow responses
and sometimes during unresponsive states. Even after
participating in the clinical trial for more than 3 months, the
patients often had problems with the device. For example,
74-year-old Uma, in her fifth month in the clinical trial, was
very frustrated during the contextual inquiry. A portion of the
transcript (from the second minute until the fifth minute) of
Uma is as follows:
Uma: I don’t know what’s wrong with it; it suddenly
slowed down.
Researcher: Did it slow down today or—?
Uma: No, it has been doing this for a few days. I was
talking to the lady [Nurse1] on the phone and—come
on.
Uma called “come on” to the device after being frustrated with
the device for not responding to her touches.
Uma: I have to go through this every morning.
It’s—aaah.
Uma ceaselessly showed frustration, sighed heavily with hand
gestures toward the device, and talked to the device.
Uma: I don’t know whether it’s because
it’s—aaaahhhhh. [more frustration]
After the fifth minute, Uma was able to use the device after
restarting it and being helped by the researcher.
Difficulty in Measurement of Blood Pressure
All but one patient (Ted) complained about difficulty with the
automatic sphygmomanometer because they had to use one arm
to put the cuff around the other arm and then press a button on
the device screen to start the automatic adjustment process
(Figure 4). It was a very difficult process for any person to do
this task alone. Heidi described it as: “It’s not really a one-man
job.”
Figure 4. Heidi (left) and Uma (right) struggling with the sphygmomanometer.
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Discussion
Overview
All the patients were more than 3 months in the clinical trial.
Yet, we saw frustrations during use of the device due to
design—the responses and limitations. There were perceived
benefits and promises if designed right. Even how the treatment
was designed was influencing patients UX. For example, T2D
patients had to measure their own blood pressure, which is not
an easy task. Even the researchers could not measure blood
pressure accurately with the same device during some practices.
Design Implications for Future Telehealth for T2D
The patients wanted to see their own data meaningfully
presented through graphs. And a wireless device was preferred
due to mobility. Glucometer comfort, inclusion of all medication
names, and wireless connectivity are essential for a device for
T2D.
Domestication of the Device
The patients treated the device like regular domestic technology.
Stable and compelling routines at home influences the use of
domestic technologies [18]. Therefore, considerations of
people’s routine activities and contexts are essential to inform
the design; otherwise, people end up excluding those
technologies. Our results resemble Crabtree’s findings [19]; in
domestic settings, the patients might have multiple other
gadgets, and the telehealth device became one of them. Ted
placed his device in his living room beside his reclining chair,
which shows comfort as a reason. Other participants, such as
Vince and Yanicka, chose their device locations based on
convenience.
Influence on Patients From the Use of the Technology
The study of how to design technology to motivate behavioral
change has been of increased interest to researchers and
industrial practitioners due to the widespread use of technology,
such as computers, mobile phones, iPads, etc. Persuasive
technology is “a computing system, device, or application
designed to change a person’s attitude or behavior in a certain
way” without using coercion or deception [20]. Additionally,
technology is never neutral; it influences users in one way or
another [21,22]. Persuasive technology is designed to target a
specific behavioral change of the users intentionally. These
study patients mentioned different levels of influence on their
lives from the use of the device. Heidi said she received extra
motivation from this device to do her regular blood glucose
check. Vince felt motivated to manage his blood glucose because
the device motivated him to check it. Pete was motivated by
placing the device beside his bed. Serena and her son mentioned
during the interview that Serena was more accountable to look
after her blood glucose while using the telehealth device.
Serena’s son stated that Serena was more aware of her blood
glucose and food intake after using the device. Additionally,
Vince, Heidi, Pete, and Ted also mentioned an improvement in
awareness.
This telehealth device was not designed to motivate, build habits,
or create awareness among patients. But this device did show
the potential to change patients’ behavior if it had been
integrated with persuasive technology strategies [23]. It could
be improved by targeting specific behaviors, such as healthy
eating habits [24] of T2D patients, to help manage their
conditions better.
Categorization of the Patients as Users
All patients did not use the device with the same degree of
interest. We found different levels of interest in the patients
based on the observations and their explanations during stages
1 and 2 of the CUE. Our persona categorization of the nine
patients in the CUE includes enthusiastic, tolerant, indifferent,
and resistant patients [6]. These categories need to be validated
with a higher population of patients.
Limitations of the Research
The CUE was conducted with a sample size of nine patients.
To generalize these findings across the T2D population, future
work should include a higher number of patients and expand
quantitatively on findings of this research.
Comparison With Prior Work
Most health researchers advocate larger, well-designed,
controlled studies to gather evidence [25-27]. However, there
is a gap. There are no studies that evaluate the effectiveness of
telehealth in daily practice from patients’ lives; rather the studies
strengthen current evidence [28]. This research is an approach
to bridge that gap and increase evaluation of telehealth from a
user (patient) perspective through CUE, unlike some recent
usability studies with telehealth. For example, a study conducted
for patients with T2D showed that usability improvements
increased the acceptability by 57%, but studies of this sort are
often explored to gather quantitative evidence only. They do
not understand patients, unlike the CUE. To our knowledge,
many studies conducted qualitative research as a component
added onto a clinical trial, but no study has been conducted
from ICT researchers from an HCI perspective that looks at
telehealth and its impact on patients as users of these
technologies. In another study, a 2016 investigation of patients
with T2D who dropped out of an eHealth intervention used
semistructured interviews to explore the reasons why patients
opt out of a telehealth trial [29]. The CUE in this research used
both contextual inquiry with semistructured interviews versus
just semistructured interviews and uncovered both satisfied and
dissatisfied patients [30].
Past qualitative work reported on telehealth-delivered
educational interventions [31] and telephone interventions [31]
did not improve medical conditions in T2D patients. Studies
such as CUE can explore why some interventions worked or
did not work. This kind of investigation had never been
conducted in a clinical trial from an HCI perspective by ICT
researchers. Generally, HCI evaluation is done during the
development phase but, in this study, it was conducted in the
rollout phase. Although domestication research had been
undertaken with technology and users, domestication of a
telehealth in-home monitoring device (in this case for T2D) has
not been researched in the past until this study.
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Another stream of studies took behavior change approaches in
T2D management [32]. The CUE aligns more with this line of
research. Researchers in the future should explore more in-depth
into the role of the technology intervention and T2D
management with approaches like CUE.
Conclusions
Investigation of interactions between patients and a technology
are critical in telehealth because it affects the overall outcome
of a treatment. Disregard for the needs of patients, social and
cultural habits, and the complex nature of health care systems
results in relatively low impact and uptake of telehealth and
eHealth technologies [33]. Some eHealth and telehealth
interventions show dropout rates of up to 80% [34,35], but there
is little knowledge about the UX-related dropouts. Therefore,
we investigated a telehealth clinical trial through the HCI
approach and investigated patients’ UX in a T2D clinical trial
in Northern Queensland. We discovered that patients benefited
from using the in-home monitoring device to manage their T2D
regarding awareness, motivation, involvement, etc. Patients’
negative experiences with the technology—not all the patients
engaged with the telehealth device equally—and design
recommendations for future T2D telehealth were also found.
We urge a global movement to advocate and practice HCI to
complement all telehealth clinical trials and understand patients’
UX.
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